Rising to the challenges of rare disease treatmentSoligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
Specialized BioTherapeutics Pipeline
Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|---|---|---|---|
| HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL) | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| SGX942 for Oral Mucositis Treatment | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| SGX203 for Pediatric Crohn’s Disease | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| SGX302 for Mild to Moderate Psoriasis | ||||
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
Orphan and/or Fast Track Designation
Denotes funding by NIH, BARDA, DTRA and/or FDA.
Public Health Solutions Pipeline
Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.
| Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
|---|---|---|---|---|
| RiVax® to Prevent Ricin Poisoning | ||||
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
| SGX943 for Infectious Disease | ||||
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
| ThermoVax®: Thermostabilized Vaccines for Global Use | ||||
Proof-of-Concept | IND | Phase 1 | Phase 2/3 | Market |
Orphan and/or Fast Track Designation
Denotes funding by NIH, BARDA, DTRA and/or FDA.
The Latest
Resources
News
External Link
Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63(6):984-90.
Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63(6):984-90.
External Link
Soligenix Corporate Update Letter – Key Highlights and Upcoming Catalysts
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…